Alamar Biosciences, Inc. Common Stock

Several biotech stocks reached 52-week highs on August 11, 2026, driven by quarterly reports and regulatory progress. Alamar Biosciences surged over 30% to $38.54 after reporting second-quarter revenue of $29.43 million and projecting full-year 2026 revenue between $116 million and $120 million. Dyne Therapeutics rose to $27.13 following FDA acceptance of its Biologics License Application for Z-Rostudirsen, with a decision expected in January 2027. Cullinan Therapeutics gained over 7% to $19.82 after narrowing its quarterly loss and announcing plans for Phase 2 trials in autoimmune diseases. Cardinal Health climbed to $258.30 on fiscal 2026 revenue of $254.2 billion and net earnings of $1.7 billion. DexCom reached $89.56 after reporting 13% second-quarter revenue growth to $1.31 billion and forecasting full-year revenue of $5.18 billion to $5.25 billion.

Alamar Biosciences has launched the NULISAseq Immune 340 Panel, a multiplex immunoassay that measures approximately 340 immune-related proteins from a single sample. The panel expands on the company's NULISAseq Inflammation Panel 250 and is designed to capture low-abundance targets such as cytokines, chemokines, and immune checkpoint inhibitors that are often undetectable by standard platforms. Alamar's founder and CEO Dr. Yuling Luo stated that the panel provides an unprecedented view of immune system activity, which could accelerate biomarker discovery and the development of new therapies and diagnostics. Bailin Zhang, Head of Exploratory Biomarkers in Translational Medicine at Sanofi, noted that the panel's combination of breadth and sensitivity opens new possibilities for biomarker discovery and patient stratification by enabling simultaneous measurement of proteins related to immune mechanisms of action, drug resistance, and toxicity.

Several biotech stocks reached 52-week highs on July 14, 2026, driven by positive clinical data and new program launches. Hemab Therapeutics hit $42.03 after reporting encouraging Phase 2 results for its Von Willebrand's disease candidate HMB-002 and unveiling a new drug candidate, HMB-003, for heavy menstrual bleeding. Alamar Biosciences touched $29.43 following a partnership with U.S. research universities to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer's biomarker discovery. Progyny rose over 4% to $32, with the company projecting full-year 2026 revenue between $1.365 billion and $1.405 billion, a 5.9% to 9% increase. 10x Genomics closed at a 52-week high of $43.98 after recent collaborations, including a bladder cancer diagnostic project with Cleveland Clinic, and expects 2026 revenue of $600 million to $625 million. Viemed Healthcare peaked at $12.61, forecasting net revenues of $312 million to $320 million for 2026.

Alamar Biosciences has launched a nationwide proteomics initiative with multiple leading research universities to accelerate biomarker discovery for Alzheimer’s disease and related dementias. The study will use Alamar’s NULISAseq Neuro 220 multiplex panel, including a new eMTBR-Tau assay, to analyze approximately 21,000 plasma samples from 10,000 participants across U.S. Alzheimer’s Disease Research Centers. Led by Dr. Sarah Biber of Washington University, Dr. Sterling Johnson of the University of Wisconsin, and Dr. Tatiana Foroud of Indiana University’s NCRAD, the project is part of the CLARiTI portfolio and supported by the Alzheimer’s Association, the Robertson Foundation, and an anonymous foundation. All resulting proteomic data will be linked via National Alzheimer’s Coordinating Center identifiers and made openly available to the global research community, with a national data challenge planned to spur AI-driven analysis.

Alamar Biosciences announced that its NULISA platform will be featured in more than 140 poster and session presentations at the Alzheimer's Association International Conference in London, reflecting rapid adoption of its technology in Alzheimer's research. The company will host a workshop showcasing new data on its eMTBR-Tau and BD-pTau217 assays, which were measured alongside over 220 disease-related proteins on a single NULISAseq panel. Evidence indicates that combining BD-pTau217 and eMTBR-Tau improves discrimination across the Alzheimer's continuum compared to single-analyte pTau-217 measurement alone, supporting earlier detection and more precise disease staging. The presentations span presymptomatic, prodromal, and diagnosed Alzheimer's populations, highlighting the platform's broad applicability.

Cathie Wood, CEO and CIO of Ark Invest, purchased shares of Space Exploration, Roblox, and Alamar Biosciences on Monday, marking her only buys of the day. SpaceX, which recently went public, has seen its stock fall nearly a third from its peak but remains one of just seven U.S.-listed companies with a market cap above $2 trillion. Roblox shares dropped 8% on Tuesday and have lost more than half their value over the past year, despite reporting 132 million daily active users and 31 billion hours of engagement in the first quarter. Alamar Biosciences, a commercial-stage proteomics company that went public in April at $17 per share, nearly doubled its revenue to $26 million in its first quarterly report as a public company.